Australia’s health regulator has stood by its recent testing of medical cannabis products and denied its initial analysis was wrong.

The Therapeutic Goods Administration (TGA) was forced to defend its processes after third-party testing of five products returned different results to that of the regulator.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

It said a number of factors may have contributed to the varying results, and ruled out any move to standardise individual testing labs.

The third-party tests appeared to exonerate three of five products that had earlier failed a TGA potency audit.

A report published by the TGA had named two Althea products, and one each from Little Green Pharma, Spectrum Therapeutics and Bedrocan as those which “failed” its analysis.

Follow-up tests subsequently found the Althea and Spectrum products were within required limits with the other two only fractionally out.

The TGA said in a statement: “While the results from the third-party testing show different results, this does not imply that the TGA’s results are not accurate.

“A number of factors can lead to differences in results including variability within the batch [which is] particularly problematic for plant samples, the precision of the method used [which can] be affected by non-representative sample size and extraction, and accuracy of the method [which] can be affected by poor/incomplete extraction and the accuracy of the reference material used.